Publications by authors named "Francisco Garcia-Navalon"
Objectives: The S-REAL study aimed to assess the effectiveness of durvalumab as consolidation therapy after definitive chemoradiotherapy (CRT) in a real-world cohort of patients with locally advanced, unresectable stage III non-small cell lung cancer (LA-NSCLC) included in a Spanish early access program (EAP).
Methods: In this multicentre, observational, retrospective study we analysed data from patients treated in 39 Spanish hospitals, who started intravenous durvalumab (10 mg/kg every 2 weeks) between September 2017 and December 2018. The primary endpoint was progression-free survival (PFS).
Article Synopsis
- The study investigates the effectiveness and tolerability of different chemotherapy regimens (FOLFOX, CAPOX, CP, and FP) for treating HER2-negative advanced esophagogastric cancer, using data from the AGAMENON-SEOM Spanish registry between 2008 and 2021.
- Results indicate that FOLFOX significantly improves progression-free survival (PFS) compared to the CP regimen, although treatment durations were similar among all groups.
- Adverse effects varied by regimen, with higher rates of fatigue and neuropathy seen in FOLFOX, while CP showed notable incidences of hand-foot syndrome and thromboembolic events.
Background: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab.
Methods: Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included.
Article Synopsis
- The study compared the effectiveness of ramucirumab-paclitaxel versus traditional chemotherapy in second-line treatment for advanced gastroesophageal cancer (aGEC), focusing on patients' HER2 status.
- Patients from the AGAMENON-SEOM registry treated between 2016 and 2021 were analyzed for progression-free survival (PFS) and overall survival (OS) using statistical methods.
- Results indicated that ramucirumab-paclitaxel significantly improved both PFS and OS compared to chemotherapy, regardless of HER2 status, highlighting its potential as a better treatment option for aGEC patients.
One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study.
BMJ Support Palliat Care
December 2023
Objectives: Naloxegol is a peripherally acting µ-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in patients with cancer in a real-world study.
Methods: This one-year prospective study included patients older than 18 years, with active oncological disease who were under treatment with opioids for pain control and Karnofsky≥50 and OIC with inadequate response to treatment with laxative (s).
Management of chronic pain is crucial to improve the quality of life of cancer and palliative care patients. Opioid-based treatments used to control pain can be prolonged over time. Unfortunately, constipation is one of the most disturbing adverse effects of long-term use of opioids.
View Article and Find Full Text PDFArticle Synopsis
- Opioid-induced constipation (OIC) affects up to 63% of cancer patients, prompting a study to evaluate the quality of life and effectiveness of naloxegol for those with OIC.
- An observational study involved 126 cancer patients who showed inadequate laxative response and were treated with naloxegol, using specific questionnaires to measure outcomes over three months.
- Results showed significant improvements in quality of life, increased bowel movements, and pain management after 15 days of treatment, with a good safety profile and only a small percentage experiencing mild to moderate gastrointestinal side effects.
Background: We sought to develop and externally validate a nomogram and web-based calculator to individually predict the development of serious complications in seemingly stable adult patients with solid tumours and episodes of febrile neutropenia (FN).
Patients And Methods: The data from the FINITE study (n=1133) and University of Salamanca Hospital (USH) FN registry (n=296) were used to develop and validate this tool. The main eligibility criterion was the presence of apparent clinical stability, defined as events without acute organ dysfunction, abnormal vital signs, or major infections.